About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

GIOTRIF rPMS in Korean Patients With NSCLC

NCT02285361·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

19–110

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Patients who have been started on GIOTRIF® in accordance with the approved label in Korea
2. Age = 19 years at enrolment
3. Patients who have signed on the data release consent form

You may not be if

1. Known hypersensitivity to afatinib or any of its excipients
2. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
3. Patients for whom GIOTRIF® is contraindicated according to the local label

The record

StatusCompleted

PhaseNo phase

Taking part1,272

StartedOct 2014

UpdatedFeb 24, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Where1

Multiple Locations, South Korea

Clareo Health | GIOTRIF rPMS in Korean Patients With NSCLC